News and Press Releases
Press releases
CORRECTION FROM SOURCE: Theralase® to Present Groundbreaking Research at ASTRO 2025
Press ReleaseTheralase® will present preclinical data comparing radiation-activated Rutherrin® versus radiation alone at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits; clinical trials for various cancers begin...
Theralase® to Present Groundbreaking Research at ASTRO 2025
Press ReleaseTheralase®’s Rutherrin® is 100x more effective than radiation alone in preclinical cancer models, showing tumor targeting, immune activation, and improved survival; Phase I/II clinical trials start early 2026 targeting multiple cancers....
Theralase® Provides Corporate Update
Press ReleaseTheralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research...
Theralase® Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Press ReleaseTheralase® presented interim Phase II data showing Ruvidar™’s strong safety and efficacy in treating BCG-unresponsive bladder cancer, with durable complete responses, no serious drug-related adverse events, and potential for...
Theralase® Discovers New Mechanism of Action of Lead Drug
Press ReleaseTheralase® announces Ruvidar™ inhibits Deubiquitinating Enzymes (DUBs), a key factor in cancer and drug resistance. This dual action—blocking DUBs and inducing oxidative stress—makes Ruvidar™ a promising cancer therapy...
Theralase® Closes Non-Brokered Private Placement
Press ReleaseTheralase® closes $419,124 private placement financing by issuing 1,995,829 units at CAD 0.21 each, with warrants exercisable at CAD 0.32 for 5 years. Funds will support Phase II bladder cancer trials, HSV treatment R&D, Rutherrin®...
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Press ReleaseRuvidar™ (1%) showed superior efficacy in healing HSV-1 lesions in mice versus FDA-approved Acyclovir (5%) and Abreva (10%). Ruvidar™ requires fewer applications and works via novel electrostatic repulsion mechanisms...
Ruvidar Demonstrates 7 Year Complete Response
Press ReleaseA BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat...
Ruvidar Effective in the Treatment of Herpes
Press ReleaseRuvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025....
Theralase® Releases 2024 Annual Financial Statements
Press ReleaseTheralase® reported a slight revenue decline in 2024 but reduced net loss, advanced clinical trials for cancer and Parkinson’s treatments, showed promising results in HSV and lymphoma studies, and plans FDA resubmissions....
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
